

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Shigeki MACHIDA et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_1242A
Filed July 28, 2006 :

AGENT FOR PROPHYLACTIC AND/OR
THERAPEUTIC TREATMENT OF RETINOPATHY
[Corresponding to PCT/JP2005/001204
Filed January 28, 2005]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/_____; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**
- (2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Shigeki MACHIDA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 28, 2006

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: July 28, 2006

ATTY DOCKET NO.
2006_1242ASERIAL NO.
NEW

10/587860

APPLICANT
Shigeki MACHIDA et al.

IAP5 Rec'd PCT/PTO 28 JUL 2006

FILING DATE
July 28, 2006

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AD	8-231416	9/1996	JP			Abstract	
	AE							
	AF							
	AG							
	AH							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Y. Miura et al., "Hepatocyte Growth Factor Stimulates Proliferation and Migration During Wound Healing of Retinal Pigment Epithelial Cells <i>In Vitro</i> ", Jpn. J. Ophthalmol., Vol. 47, pp. 268-275, 2003.
	AJ	H. Shibuki et al., "Expression and Neuroprotective Effect of Hepatocyte Growth Factor in Retinal Ischemia-Reperfusion Injury", Investigative Ophthalmology & Visual Science, Vol. 43, No. 2, pp. 528-536, February 2002.
	AK	I. Grierson et al., "Hepatocyte Growth Factor/Scatter Factor in the Eye", Process in Retinal and Eye Research, Vol. 19, No. 6, pp. 779-802, 2003, (Abstract only).
	AL	E. H. Van Aken et al., "Invasion of Retinal Pigment Epithelial Cells: N-cadherin, Hepatocyte Growth Factor, and Focal Adhesion Kinase", Investigative Ophthalmology & Visual Science, Vol. 44, No. 2, pp. 463-472, February 2003.
	AM	P. M. He et al., "Retinal Pigment Epithelial Cells Secrete and Respond to Hepatocyte Growth Factor", Biochemical and Biophysical Research Communications, Vol. 249, pp. 253-257, 1998.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.